BRPI1014775A2 - tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta - Google Patents

tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta

Info

Publication number
BRPI1014775A2
BRPI1014775A2 BRPI1014775A BRPI1014775A BRPI1014775A2 BR PI1014775 A2 BRPI1014775 A2 BR PI1014775A2 BR PI1014775 A BRPI1014775 A BR PI1014775A BR PI1014775 A BRPI1014775 A BR PI1014775A BR PI1014775 A2 BRPI1014775 A2 BR PI1014775A2
Authority
BR
Brazil
Prior art keywords
pkc
immune disorders
vivo treatment
theta inhibitors
theta
Prior art date
Application number
BRPI1014775A
Other languages
English (en)
Inventor
Alexandra Zanin-Zhorov
Maryanne Brown
Michael Dustin
Original Assignee
Boehringer Ingelheim Int
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42332785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014775(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Univ New York filed Critical Boehringer Ingelheim Int
Publication of BRPI1014775A2 publication Critical patent/BRPI1014775A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI1014775A 2009-04-28 2010-04-28 tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta BRPI1014775A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17323709P 2009-04-28 2009-04-28
PCT/US2010/032707 WO2010126967A1 (en) 2009-04-28 2010-04-28 Ex-vivo treatment of immunological disorders with pkc-theta inhibitors

Publications (1)

Publication Number Publication Date
BRPI1014775A2 true BRPI1014775A2 (pt) 2016-04-19

Family

ID=42332785

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014775A BRPI1014775A2 (pt) 2009-04-28 2010-04-28 tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta

Country Status (14)

Country Link
US (1) US20120196919A1 (pt)
EP (1) EP2445503A1 (pt)
JP (1) JP2012525403A (pt)
KR (1) KR20120005460A (pt)
CN (1) CN102421435A (pt)
AU (1) AU2010241701A1 (pt)
BR (1) BRPI1014775A2 (pt)
CA (1) CA2760305A1 (pt)
CL (1) CL2011002690A1 (pt)
EA (1) EA201101568A1 (pt)
IL (1) IL215939A0 (pt)
MX (1) MX2011011290A (pt)
NZ (1) NZ595331A (pt)
WO (1) WO2010126967A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008293431B2 (en) 2007-08-31 2013-07-04 Cytopherx, Inc. Selective cytopheresis devices and related methods thereof
JP5937003B2 (ja) 2009-05-18 2016-06-22 セラコス・インコーポレイテッドＴｈｅｒａｋｏｓ， Ｉｎｃ． 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性ｔ細胞のエクスビボ増加方法
JP2013531011A (ja) 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
EP2585447A2 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
MX2013001869A (es) 2010-08-17 2013-06-28 Vertex Pharma Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae.
CN103260670A (zh) 2010-10-15 2013-08-21 塞托弗尔克斯股份有限公司 细胞分离灌流器及其用途
US20140186372A1 (en) * 2011-06-16 2014-07-03 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
AU2012286853A1 (en) 2011-07-26 2013-05-02 Vertex Pharmaceuticals Incorporated Thiophene compounds
CA2860831C (en) 2012-01-09 2024-09-10 Seastar Medical, Inc. CARTRIDGE AND METHOD FOR INCREASING MYOCARDIAL FUNCTION
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
AU2015348043B2 (en) 2014-11-21 2019-08-22 F2G Limited Antifungal agents
CA2985816A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
US10993959B2 (en) 2015-09-04 2021-05-04 Regents Of The University Of Minnesota Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs)
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
CA3253342A1 (en) 2016-05-13 2026-03-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
CA3109954A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
JP7652690B2 (ja) 2018-11-15 2025-03-27 ザ ジェネラル ホスピタル コーポレイション アゴニスト性腫瘍壊死因子受容体スーパーファミリーポリペプチド
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1438053T3 (da) * 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
AU2003290688B8 (en) * 2002-11-08 2008-04-24 Tolerx, Inc. Molecules preferentially associated with effector T cells and methods of their use
DE602004022633D1 (de) * 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
WO2006014482A1 (en) * 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta

Also Published As

Publication number Publication date
AU2010241701A1 (en) 2011-10-13
KR20120005460A (ko) 2012-01-16
IL215939A0 (en) 2012-01-31
MX2011011290A (es) 2012-02-13
CA2760305A1 (en) 2010-11-04
CN102421435A (zh) 2012-04-18
NZ595331A (en) 2013-08-30
CL2011002690A1 (es) 2012-04-27
JP2012525403A (ja) 2012-10-22
US20120196919A1 (en) 2012-08-02
WO2010126967A1 (en) 2010-11-04
EP2445503A1 (en) 2012-05-02
EA201101568A1 (ru) 2012-05-30

Similar Documents

Publication Publication Date Title
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
EP2501352A4 (en) NON-INVASIVE GREASE REMOVAL
BRPI1015238A2 (pt) diamidas de azetidilina como inibidores de monoaciglicerol lipase
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
PL2506850T3 (pl) Sposoby podawania terapii pirfenidonem
IL215939A0 (en) Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
PT3509341T (pt) Adaptação de parâmetros de transferência
EP2385843A4 (en) TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
PT2640375T (pt) Método de tratamento da nefropatia induzida por contraste
PL2405869T3 (pl) Leczenie otyłości
PL2601979T3 (pl) Sposób sterylizacji
PT3412687T (pt) Métodos de tratamento de dlbcl
EP2442645A4 (en) choline
GB0915515D0 (en) Treatment of vasculoproliferative conditions
EP2456440A4 (en) Quinolinone PDE2 INHIBITORS
HUE040085T2 (hu) PDE7 inhibitorok alkalmazása mozgási rendellenességek kezelésére
DOP2011000397A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
PL2435825T3 (pl) Sposoby leczenia chorób
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
BRPI1008744A2 (pt) hidrotratamento de caboidratos
HUE033690T2 (hu) Terápiás szer hangulatzavarokra
IL206491A0 (en) Treatment of produce
EP2517095A4 (en) ABOUT STORAGE HANDLING

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.